RecruitingPhase 2NCT05753566

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Principal Investigator
Chief physician of Department of Urology
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intervention
Rezvilutamide(drug)
Enrollment
96 enrolled
Eligibility
40 years · MALE
Timeline
20232028

Study locations (2)

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05753566 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials